Turning thet tide against tuberculosis . As the world's deadliest infectious disease surges, GSK and partners are pioneering ...

Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

Endurance Techn, Solar Ind, GlaxoSmithKline, Gland, and Motilal Oswal marked their presence among the top gainers in the ...

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

Patients with asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, ...

Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin approved for add-on severe asthma treatment in 2021 ...

Microsoft launches Discovery, its new enterprise AI platform from Build 2025, set to accelerate scientific R&D via collaborative AI agents & a graph-knowledge engine for faster innovation.

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

Microsoft launches Discovery platform that uses agentic AI to compress years of scientific research into days, transforming R ...

Microsoft Corp. today announced the launch of Microsoft Discovery, a new enterprise-grade artificial intelligence platform ...

A low-carbon version of a triple combination pMDI inhaler indicated for adults with moderate-to-severe COPD has been approved by the MHRA.